Piper Sandler Maintains Overweight on Crinetics Pharmaceuticals, Maintains $97 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a $97 price target.
July 02, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a $97 price target.
The reaffirmation of an Overweight rating and a high price target of $97 by a reputable analyst from Piper Sandler is likely to boost investor confidence in Crinetics Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100